Three stories from the weekend reshape their respective markets. The Supreme Court ruled to maintain mifepristone access while litigation continues, resolving the near-term regulatory uncertainty that has hung over the industry since the 5th Circuit decision on May 1. The drug can still be prescribed at pharmacies or by mail without requiring in-person visits. Second, the FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer—a landmark expansion that brings the ADC modality into the curative-intent setting for the first time in breast cancer. The approval is based on the Phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials. For Daiichi Sankyo, which just announced a $14.6 billion oncology revenue target by 2030, this is the kind of label expansion that moves the franchise toward that goal. Third, the FDA approved a Tecentriq label expansion alongside Natera’s Signatera as a companion diagnostic, creating the most significant commercial validation of ctDNA-based liquid biopsy technology in 2026. And in a development that adds a new variable to every China-related pharma decision, STAT reported that Beijing issued Decree No. 834 giving itself sweeping powers to investigate and sanction foreign companies whose commercial decisions are deemed to harm China’s industrial chain security.
SCOTUS Preserves Mifepristone Access — Near-Term Uncertainty Resolved
What Happened: The Supreme Court ruled to maintain access to mifepristone while litigation continues. The drug can still be prescribed at pharmacies or by mail without requiring in-person visits. The 5th Circuit’s May 1 ruling reinstating nationwide in-person dispensing requirements remains blocked.
What This Means
This resolves the immediate access disruption we have tracked since Alito’s administrative stay on May 4. For two weeks, the pharmaceutical industry, patients, and providers operated under uncertainty about whether federal courts could override FDA dispensing decisions for an approved drug. That near-term uncertainty is now resolved.
The underlying legal question—whether federal courts can substitute their judgment for the FDA’s on how approved drugs should be dispensed—remains unresolved and could return to the Court on the merits. The precedent risk we outlined in our May 5 coverage has not been eliminated, only deferred. But for companies whose commercial models depend on telehealth prescribing, mail-order distribution, or modified REMS provisions, the immediate threat has passed.
Enhertu Approved for Early Breast Cancer in Landmark ADC Expansion
What Happened: The FDA approved Enhertu (trastuzumab deruxtecan) on May 16 for both neoadjuvant (before surgery) and adjuvant (after surgery) treatment of HER2-positive early breast cancer. The approval is based on the Phase 3 DESTINY-Breast11 (neoadjuvant) and DESTINY-Breast05 (adjuvant) trials. Enhertu is co-developed by AstraZeneca and Daiichi Sankyo and is already the world’s leading ADC franchise.
Why This Is a Category-Defining Moment
Until now, ADCs have been approved almost exclusively in the metastatic (incurable) setting, where they extend survival but rarely cure disease. Moving into neoadjuvant and adjuvant treatment means ADCs are now being used with curative intent—in patients whose cancers can potentially be eliminated entirely through the combination of systemic therapy and surgery.
This distinction matters enormously for both clinical practice and commercial opportunity. The early-stage breast cancer population is substantially larger than the metastatic population. Patients diagnosed with early-stage HER2-positive breast cancer typically receive systemic treatment before and/or after surgery as part of a curative treatment plan. Adding Enhertu to this setting dramatically expands the drug’s addressable patient population beyond the metastatic indications where it has already established itself as a leading therapy.
What It Means for Daiichi Sankyo’s $14.6B Oncology Target
Daiichi Sankyo announced its five-year plan on May 11 targeting $14.64 billion in oncology revenue by 2030. That target depends on Enhertu continuing to grow across its approved indications while the pipeline of next-generation ADC candidates progresses. The early breast cancer approval is the single most important label expansion for reaching that revenue goal.
Enhertu’s existing approvals in metastatic breast cancer, gastric cancer, and NSCLC generate significant revenue. Adding early breast cancer—where patient volumes are larger and treatment durations are defined by curative-intent protocols rather than progression-based endpoints—could push Enhertu toward mega-blockbuster status.
The Broader ADC Validation
The implications extend beyond Enhertu. Every ADC program in clinical development gains validation from this approval. If ADCs work in early breast cancer, the modality will be tested in early-stage lung cancer, colorectal cancer, gastric cancer, and other solid tumors. Each early-stage label expansion dramatically increases the addressable patient population relative to the metastatic setting. The $5 billion Gilead/Tubulis deal and the dozens of ADC programs across the industry all benefit from the proof-of-concept that ADCs can deliver in the curative setting.
Our Pro brief analyzes what the first ADC approval in the curative setting means for the modality’s trajectory, how it advances Daiichi Sankyo’s $14.6B target, and which ADC programs are best positioned to pursue their own early-stage label expansions. [Details below.]
Tecentriq Label Expansion with Natera Signatera Companion Diagnostic
What Happened: The FDA approved a Tecentriq (atezolizumab) label expansion on May 15 alongside Natera’s Signatera as a companion diagnostic. Signatera uses circulating tumor DNA (ctDNA) analysis to detect minimal residual disease (MRD) after surgery, identifying patients who may benefit from adjuvant immunotherapy.
Why This Is the Diagnostics Story of 2026
Liquid biopsy technology—detecting cancer-related DNA fragments circulating in the blood—has been developing for years. Natera’s Signatera has been used as a laboratory-developed test with growing adoption. But the companion diagnostic approval with Tecentriq elevates the technology to a fundamentally different position.
Now Signatera is an FDA-approved part of the treatment algorithm: patients test positive for ctDNA after surgery, and the test result directly informs the decision to prescribe Tecentriq. This creates a reimbursement pathway that is cleaner than the laboratory-developed test model. It creates a clinical workflow where the diagnostic and the treatment are linked by regulatory approval. And it creates a template that other checkpoint inhibitor manufacturers will want to replicate.
For Natera, the companion diagnostic approval establishes Signatera as more than a monitoring tool—it becomes a treatment-decision tool with a defined role in the prescribing process. For the diagnostics industry, this is the most concrete commercial validation of liquid biopsy in adjuvant oncology. The template—ctDNA-based MRD test paired with a specific immunotherapy—can be extended to other checkpoint inhibitors, other tumor types, and other treatment settings.
Our Pro brief analyzes how the companion diagnostic approval creates a template for liquid biopsy in adjuvant oncology and which companies are best positioned to pursue additional pairings. [Details below.]
Foundayo Maintenance Data Support Long-Term Dosing Strategy
BioSpace reported that patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies. Lilly is positioning Foundayo as part of a long-term obesity care strategy.
Why This Matters: One of the key concerns in the GLP-1 market is the approximately 65% one-year discontinuation rate observed across the class. Patients who stop GLP-1 therapy typically regain weight. Data showing that patients can sustain weight loss on maintenance doses of Foundayo—rather than requiring continuous high-dose injectable therapy—addresses this concern directly.
The maintenance positioning also has commercial implications. If patients can step down from injectable Mounjaro or Zepbound to oral Foundayo for maintenance, it creates a pathway where the injectable drives initial weight loss and the oral formulation sustains it. This injectable-to-oral transition could improve long-term adherence (daily pill versus weekly injection for maintenance), reduce per-patient costs, and expand the total duration of therapy across the patient journey.
Anthropic Partners with Gates Foundation on Global Health AI
Anthropic announced a four-year partnership with the Gates Foundation focused on vaccines, disease modeling, and health-system operations in lower-income countries. The partnership builds on Anthropic’s expanding life sciences footprint, which now includes the $400 million Coefficient Bio acquisition (April), Novartis CEO Narasimhan’s board appointment (April), and existing partnerships with Sanofi, Novo Nordisk, and AbbVie.
Why This Matters: This is the first Anthropic partnership focused on global health rather than pharmaceutical R&D, broadening the company’s healthcare positioning beyond drug discovery into public health infrastructure. The Gates Foundation’s focus on vaccine delivery, disease surveillance, and health-system capacity in resource-limited settings represents a different application of AI capabilities—operational optimization rather than molecular design. The partnership signals that AI companies are beginning to position themselves across the full spectrum of healthcare, from drug development to global health delivery.
China’s Decree No. 834 Threatens Western Pharma Operations
What Happened: STAT reported that China issued Decree No. 834 on April 7, the Regulations on Industrial and Supply Chain Security, giving Beijing sweeping new powers to investigate and sanction foreign companies whose commercial decisions are deemed to harm China’s industrial chain security. China’s 15th five-year plan explicitly designates biotechnology and pharmaceuticals as the centerpiece of its next industrial development phase.
What This Means for Western Pharma
The decree has direct implications for every Western pharmaceutical company with Chinese partnerships and manufacturing operations. The definition of “harm” to China’s industrial chain security is deliberately broad and vague, giving Beijing substantial discretion in determining which foreign commercial decisions warrant investigation.
For companies with significant China licensing deals—BMS/Hengrui ($15.2 billion, 13 programs), Lilly/Hengrui (via Kailera), AbbVie/Haisco, GSK/SiranBio—the risk is that China could use this decree to pressure companies into maintaining or expanding their Chinese operations, even when other considerations (BIOSECURE Act debates, Section 232 tariffs, IP protection) push in the opposite direction.
The decree does not create immediate disruption. No Western pharma company has been investigated or sanctioned under it. But it adds a new variable to the geopolitical calculus that every business development team and board of directors must now factor into China-related decisions. The China licensing wave that has defined 2026 M&A—with billions of dollars flowing from Western pharma to Chinese biotechs—now operates under a regulatory framework where Beijing has explicit authority to scrutinize how those partnerships evolve.
Our Pro brief analyzes which Western pharma partnerships are most exposed to Decree 834, what the decree means for the China licensing wave, and how the new regulations interact with the BIOSECURE Act and Section 232 tariff dynamics. [Details below.]
Strategic Themes
1. ADCs in the Curative Setting Is a Paradigm Shift, Not Just a Label Expansion
Enhertu moving from metastatic to early-stage breast cancer is not an incremental addition to the drug’s market. It is a fundamental expansion of what ADCs can do. If the modality works with curative intent—preventing cancer recurrence rather than just extending survival in incurable disease—every ADC in development gains a new strategic rationale. The early-stage oncology market is larger than the metastatic market across virtually every solid tumor type. Enhertu just opened that door for the entire modality.
2. Liquid Biopsy Just Got Its Commercial Proof-of-Concept
The Signatera companion diagnostic approval transforms ctDNA-based MRD testing from a promising technology into an FDA-validated component of the treatment algorithm. The template—test for residual cancer DNA after surgery, use the result to decide whether to prescribe immunotherapy—is replicable across tumor types and checkpoint inhibitors. This is the moment where liquid biopsy transitions from a diagnostic innovation to a commercial platform.
3. The Mifepristone Resolution Removes a Risk Premium but Does Not Eliminate the Precedent Threat
Access is preserved. The near-term disruption is over. But the legal theory that federal courts can override FDA dispensing decisions has been established in the 5th Circuit and has not been addressed by the Supreme Court on the merits. Companies whose commercial models depend on telehealth and direct-to-consumer distribution should note the resolution with relief but not treat it as permanent closure.
4. China Decree 834 Adds a New Dimension to the Geopolitical Risk Calculus
The China licensing wave has been one of the defining M&A trends of 2026. BMS, Lilly, AbbVie, and GSK have all executed major deals with Chinese biotechs. Decree 834 does not stop those deals. But it gives Beijing a tool to influence how they evolve. The tension between Western pharma’s desire for Chinese innovation access and Beijing’s desire for leverage over Western commercial decisions is now codified in Chinese law. Every BD team evaluating a China deal must now factor this into their risk assessment.
Frequently Asked Questions
What did the Supreme Court rule on mifepristone?
The Court maintained access to mifepristone while litigation continues. The drug can still be prescribed at pharmacies or by mail without in-person visits. The 5th Circuit’s nationwide dispensing restrictions remain blocked. The underlying legal question about whether courts can override FDA dispensing decisions remains unresolved on the merits.
What is the Enhertu early breast cancer approval?
The FDA approved Enhertu for neoadjuvant (before surgery) and adjuvant (after surgery) treatment of HER2-positive early breast cancer on May 16. This is based on the DESTINY-Breast11 and DESTINY-Breast05 Phase 3 trials. It marks the first time an ADC has been approved in the curative-intent breast cancer setting, expanding the drug’s addressable market significantly.
What is the Signatera companion diagnostic approval?
Natera’s Signatera, a ctDNA-based minimal residual disease test, was approved as a companion diagnostic alongside a Tecentriq label expansion on May 15. The test detects circulating tumor DNA after surgery and informs the decision to prescribe adjuvant immunotherapy. It is the most significant commercial validation of liquid biopsy technology in 2026.
What is the Foundayo maintenance data?
Patients in two trials maintained most of their weight loss after switching to Foundayo or lower-dose Zepbound from injectable incretin therapies. This supports a long-term dosing strategy where patients step down from injectables to oral maintenance, potentially improving adherence and addressing the approximately 65% one-year discontinuation rate across the GLP-1 class.
What is China Decree No. 834?
Regulations issued April 7 giving Beijing power to investigate and sanction foreign companies whose commercial decisions are deemed to harm China’s industrial chain security. The decree directly affects Western pharma companies with Chinese partnerships and manufacturing operations. Biotechnology and pharmaceuticals are designated as the centerpiece of China’s next industrial development phase.
What is the Anthropic/Gates Foundation partnership?
A four-year partnership focused on vaccines, disease modeling, and health-system operations in lower-income countries. It is the first Anthropic partnership focused on global health rather than pharmaceutical R&D, building on the company’s expanding life sciences footprint including the $400M Coefficient Bio acquisition and partnerships with Sanofi, Novo Nordisk, and AbbVie.
When is ASCO?
May 29 through June 2 in Chicago. Revolution Medicines plenary session May 31. The conference is 13 days away.
What is the RBC conference?
The RBC Global Healthcare Conference opens tomorrow (May 19) in New York. Major healthcare investor conference with strategic updates from large-cap pharma and medtech companies.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Enhertu in Curative Oncology. We analyze what the first ADC approval in the curative setting means for the modality’s commercial trajectory, how early breast cancer volumes advance Daiichi Sankyo’s $14.6B 2030 target, and which pipeline ADC programs are best positioned to pursue their own early-stage label expansions across lung, gastric, and colorectal cancers.
Signatera’s Commercial Moment. We assess how the companion diagnostic approval creates a template for liquid biopsy in adjuvant oncology, model the reimbursement and adoption dynamics, and identify which checkpoint inhibitor manufacturers are most likely to pursue their own companion diagnostic pairings with ctDNA-based MRD tests.
China Decree 834: The New Variable. We map which Western pharma partnerships are most exposed, analyze how the decree interacts with the BIOSECURE Act and Section 232 tariff dynamics, and assess what Beijing’s explicit authority over foreign pharma operations means for the China licensing wave that has defined 2026 M&A.
Plus: Mifepristone resolution implications, Foundayo maintenance data analysis, Anthropic/Gates global health positioning, ASCO 13-day countdown, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
